CoChat
Sign Up
Cited by 109Thyroid Disorders and TreatmentsUbiquitin and proteasome pathwaysGrowth Hormone and Insulin-like Growth Factors

Substrate-Induced Down-Regulation of Human Type 2 Deiodinase (hD2) Is Mediated through Proteasomal Degradation and Requires Interaction with the Enzyme’s Active Center1

Steinsapir, Jaime, Bianco, Antonio C., Buettner, Christoph, Harney, John, Larsen, P. Reed·2000·Endocrinology
DOI 10.1210/endo.141.3.7355
Open this paper in CoChat — free account

Abstract

Type 2 iodothyronine deiodinase (D2) catalyzes the first step in thyroid hormone action, the deiodination of T4 to T3. Endogenous D2 activity is posttranslationally regulated by substrate that accelerates its degradation through the ubiquitin-proteasome pathway. To understand how D2 activity correlates with D2 protein during its normal decay and rT3-induced down-regulation, HEK-293 cells, transiently expressing human D2, were labeled with Na75SeO3 and then treated with 100 microM cycloheximide (CX), 30 nM rT3, and/or 10 microM MG132, a specific proteasome inhibitor, for 2-4 h. D2 protein and enzyme activity changed in parallel, disappearing with a half-life of 2 h in the presence of CX, or 1 h when CX + rT3 were combined. Treatment with MG132 blocked these effects. We created selenocysteine (Sec) 133 to cysteine (Cys) or alanine (Ala) D2 mutants, without changing Sec 266. The CysD2 activity and protein levels were also parallel, with a similar half-life of approximately 2 h, whereas the rT3-induced D2 down-regulation required approximately 1000-fold higher rT3 concentration (30 microM) due to a proportionally higher Michaelis constant of CysD2. In similar experiments, the AlaD2 mutant retained the short half-life but was not catalytically active and not susceptible to rT3-accelerated degradation. We conclude that substrate-induced loss of D2 activity is due to proteasomal degradation of the enzyme and requires interaction with the catalytic center of the protein.

Integrity signals

Registry

Crossref · 10.1210/endo.141.3.7355

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • T4 and rT3 inhibit DIO2 by promoting its ubiquitination, which inhibits DIO2 activity and targets it for proteasomal degradation, forming an incoherent feedforward motif with T3 as the output.

    “T4 and rT3 also inhibit DIO2 by promoting its ubiquitination, which inhibits DIO2 activity and targets it for proteasomal degradation (37–40), forming an incoherent feedforward motif with T3 as the output.”

    From Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion (2022) · cites this paper as [39]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Steinsapir, J., Bianco, A. C., Buettner, C., Harney, J., & Larsen, P. R.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Larsen, P. Reed
ORCID
Venue
Endocrinology
Publisher
The Endocrine Society
Published
2000-03
Volume
141
Issue
3
Pages
1127-1135
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
DOI
10.1210/endo.141.3.7355
OpenAlex
W2119053116
Cited by
109
References
3
Citations by year
2024: 3 · 2023: 2 · 2022: 2 · 2021: 6 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 6 · 2013: 3 · 2012: 4
FWCI
5.24
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Rutgers University Community Repository (Rutgers University) (submittedVersion)
Funders
  • National Institutes of Health (NIH-R01)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK036256)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
type 2 deiodinase, reverse T3, proteasomal degradation, ubiquitin-proteasome system, selenocysteine, catalytic site, protein half-life, thyroid hormone action, enzyme activity
MeSH terms
Alanine, Amino Acid Sequence, Binding Sites, Cells, Cultured, Cycloheximide, Cysteine, Cysteine Endopeptidases, Humans, Indicators and Reagents, Iodide Peroxidase, Molecular Sequence Data, Multienzyme Complexes, Plasmids, Protein Synthesis Inhibitors, Selenium Radioisotopes, Thyroxine, Transfection, Triiodothyronine, Reverse, Down-Regulation, Mutagenesis, Proteasome Endopeptidase Complex

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review